There is still a lot of uncertainty about how the Trump administration will affect the biopharma industry. Some companies are hoping Trump’s promise to remove 75-80% of regulation will help them get their drugs to market quicker; others are worried that his vow to lower drug prices will force them to accept smaller revenues.

However, the majority of industry leaders seem to be in agreement that the President’s immigration ban, his first major initiative since taking office, will harm rather than help biopharma companies. In a letter signed by 160 biotech and VC execs, these leaders claim that the ban will ultimately strip the US of its science leadership and halt the fight against disease.

To find out more about what was said in the letter, check out the original article here

.